Tuberomammillary Nucleus Expanded V2 plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
The tuberomammillary nucleus (TMN) is the sole source of histamine in the mammalian brain, located in the posterior hypothalamus. As the histaminergic wake-promoting center, the TMN plays essential roles in arousal, attention, learning, memory, and energy homeostasis. Dysfunction of the TMN is critically implicated in neurodegenerative diseases, particularly in sleep-wake disturbances characteristic of Alzheimer's disease (AD) and Parkinson's disease (PD). [1]
The tuberomammillary nucleus occupies the ventral portion of the posterior hypothalamus, adjacent to the mammillary bodies. It is bounded: [2]
The TMN contains exclusively histaminergic neurons along with supporting glial cells: [3]
Histaminergic Neurons: The defining cell type, using histamine as their primary neurotransmitter. These neurons are uniquely identified by:
GABAergic Neurons: Local interneurons that modulate histaminergic output
Peptidergic Neurons: Co-release of substances like galanin and substance P
Key molecular markers in the TMN include: [4]
The TMN receives input from: [5]
The TMN projects widely throughout the brain: [6]
The TMN shows significant pathology in AD: [7]
Therapeutic Implications:
TMN involvement in PD includes:
PET ligands for TMN imaging
Cerebrospinal fluid histamine measurement
Sleep-wake pattern analysis
Sleep-Wake Cycle — Sleep mechanisms
Orexin System — Wake-promoting system interactions
Tuberomammillary Nucleus Expanded V2 plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
The study of Tuberomammillary Nucleus Expanded V2 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Haas and Panula, Histamine in brain function (2022). 2022. ↩︎
Shan et al. Tuberomammillary nucleus degeneration in Alzheimer's disease (2021). 2021. ↩︎
Passani and Blandina, Histamine and cognition in neurodegenerative diseases (2022). 2022. ↩︎
Roshchina and Melnik, H3 receptor antagonists for neurodegeneration (2020). 2020. ↩︎
Saper et al. Sleep-wake cycle and histaminergic system (2021). 2021. ↩︎
Blandina et al. Histamine and attention in aging (2019). 2019. ↩︎
Yu et al. Histamine and neuroinflammation in AD (2022). 2022. ↩︎